Search｜Photos & Images & Videos｜KYODO NEWS IMAGES INC

Kariko, Weissman win Nobel medicine prize for COVID mRNA vaccine work

University of Pennsylvania professor Drew Weissman arrives at the venue of a press conference at the university in Philadelphia, the United States, on Oct. 2, 2023, after being awarded this year's Nobel Prize in physiology or medicine jointly with his Hungarian research partner Katalin Kariko for their work leading to the development of COVID-19 vaccines using a new messenger RNA technology.

E

Kariko, Weissman win Nobel medicine prize for COVID mRNA vaccine work

Hungary's Katalin Kariko (L) and her American research partner Drew Weissman attend a press conference at the University of Pennsylvania in Philadelphia, the United States, on Oct. 2, 2023, after being awarded this year's Nobel Prize in physiology or medicine for their work leading to the development of COVID-19 vaccines using a new messenger RNA technology.

E

Kariko, Weissman win Nobel medicine prize for COVID mRNA vaccine work

Hungarian scientist Katalin Kariko arrives at the venue of a press conference at the University of Pennsylvania in Philadelphia, the United States, on Oct. 2, 2023, after being awarded this year's Nobel Prize in physiology or medicine jointly with her American research partner Drew Weissman for their work leading to the development of COVID-19 vaccines using a new messenger RNA technology.

E

French pharma giant Sanofi deepens vaccine cooperation with China's Shenzhen

STORY: French pharma giant Sanofi deepens vaccine cooperation with China's Shenzhen DATELINE: April 6, 2023 LENGTH: 0:02:19 LOCATION: SHENZHEN, China CATEGORY: ECONOMY/HEALTH SHOTLIST: 1. various of the signing ceremony 2. SOUNDBITE 1 (English): THOMAS TRIOMPHE, Executive vice president, Head of Vaccines, Sanofi 3. various of Pingshan district 4. SOUNDBITE 2 (English): THOMAS TRIOMPHE, Executive vice president, Head of Vaccines, Sanofi 5. SOUNDBITE 3 (English): THOMAS TRIOMPHE, Executive vice president, Head of Vaccines, Sanofi STORYLINE: French pharmaceutical giant Sanofi and Pingshan district government in China's Shenzhen on Tuesday signed a letter of intent on vaccine cooperation. The two sides agreed to accelerate the introduction of innovative vaccines to the Chinese market and promote innovative development of biopharmaceutical industry in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA). SOUNDBITE 1 (English): THOMAS TRIOMPHE, Executive vice president, Head of Vaccines, Sanofi "It's a pleasur

E

Int'l pharmacy exhibition held in Algeria

STORY: Int'l pharmacy exhibition held in Algeria DATELINE: Feb. 17, 2023 LENGTH: 00:03:27 LOCATION: Algiers CATEGORY: HEALTH SHOTLIST: 1. various of the fair 2. SOUNDBITE (Arabic): MUSTAPHA KESSACI, Spokesperson for SAIDAL Group 3. various of the fair STORYLINE: The 17th International Pharmacy Exhibition (SIPHAL 2023) is being held in Algiers, bringing together over 150 local and foreign players in the pharmaceutical industry. This year's fair, which runs from Wednesday to Saturday, is themed "Reaching markets for improving strategy." It provides an opportunity for Algerian and foreign pharmaceutical companies to showcase their capabilities and establish partnership projects. SOUNDBITE (Arabic): MUSTAPHA KESSACI, Spokesperson for SAIDAL Group "SAIDAL has made significant progress in recent years, particularly with the successful development of an anti-COVID-19 vaccine in partnership with China, with whom we share a strong relationship. As a result, we have plans to launch more collaborative projects in

E

Yearender: Xinhua's top 10 world news events in 2022

(221230) -- BEIJING, Dec. 30, 2022 (Xinhua) -- This photo taken on Aug. 31, 2022 shows the production line of COVID-19 vaccine under the Butantan Institute in the state of Sao Paulo, Brazil. Since June 2020, Chinese biopharmaceutical company Sinovac has carried out cooperation with the Butantan Institute to conduct a number of clinical studies, the most important of which is the Phase III clinical trial of the COVID-19 vaccine. Xinhua's top 10 world news events in 2022 Persistent COVID-19 pandemic profoundly shapes world The persistent COVID-19 pandemic has caused tremendous damage to people's lives and health, had a profound impact on the world economy and people's work and life, and exacerbated supply chain disruptions and labor shortages. Putting people and their lives first, the Chinese government has been optimizing its response measures, and has achieved major positive results in coordinating epidemic prevention and control with socioeconomic development. Countries worldwide should focus o

E

India's drug controller clears Bharat Biotech's nasal vaccine against COVID-19 for emergency use

STORY: India's drug controller clears Bharat Biotech's nasal vaccine against COVID-19 for emergency use DATELINE: Sept. 7, 2022 LENGTH: 00:01:31 LOCATION: New Delhi CATEGORY: HEALTH SHOTLIST: 1. various of of India gate 2. various of hospital area 3. various of vaccination centre 4. various of traffic STORYLINE: India's federal health minister Mansukh Mandaviya said on Tuesday the Central Drugs Standard Control Organisation (CDSCO) has cleared vaccine maker Bharat Biotech's nasal vaccine against COVID-19 for emergency use. Mandaviya has described the development as a big boost to the ongoing fight against COVID-19. "Big Boost to India's Fight Against COVID-19! Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by CDSCO for primary immunization against COVID-19 in 18 plus age group for restricted use in emergency situation," Mandaviya said in a brief statement posted on social media. The health minister said the step would further stre

E

BOTSWANA-GABORONE-COVID-19 VACCINE-MANUFACTURING PLANT-LAUNCH

(220329) -- GABORONE, March 29, 2022 (Xinhua) -- Botswana President Mokgweetsi Masisi (L) attends a ceremony for the launch of the NantBotswana vaccine manufacturing plant in Gaborone, Botswana, on March 28, 2022. The NantBotswana plant will produce Pula Corbevax vaccine against COVID-19 developed in partnership with Texas Children's Hospital Center for Vaccine Development and Baylor College of Medicine, said Masisi during the ceremony. (Photo by Tshekiso Tebalo/Xinhua)

E

BOTSWANA-GABORONE-COVID-19 VACCINE-MANUFACTURING PLANT-LAUNCH

(220329) -- GABORONE, March 29, 2022 (Xinhua) -- Botswana President Mokgweetsi Masisi (L) and Chief Executive Officer (CEO) of NantWorks Patrick Soon-Shiong, attend a ceremony for the launch of the NantBotswana vaccine manufacturing plant in Gaborone, Botswana, on March 28, 2022. The NantBotswana plant will produce Pula Corbevax vaccine against COVID-19 developed in partnership with Texas Children's Hospital Center for Vaccine Development and Baylor College of Medicine, said Masisi during the ceremony. (Photo by Tshekiso Tebalo/Xinhua)

E

China honors commitment to cooperation with Africa: FM

STORY: China honors commitment to cooperation with Africa: FM DATELINE: March 7, 2022 LENGTH: 00:02:17 LOCATION: Beijing CATEGORY: POLITICS SHOTLIST: 1. various of Chinese State Councilor and Foreign Minister Wang Yi meeting the press STORYLINE: China honors its commitment to cooperation with Africa and never makes empty promises, State Councilor and Foreign Minister Wang Yi said Monday. Over the years, China has built over 10,000 km of railways, up to 100,000 km of highways, nearly 100 ports, and innumerable hospitals and schools in Africa, Wang told a press conference. "These are not 'debt traps,' but monuments of cooperation," Wang said. Each year, Chinese foreign minister starts his overseas visits with a trip to Africa, reflecting the country's firm support for Africa's development and rejuvenation, according to Wang. This year, China will fully deliver its pledge of providing 1 billion doses of vaccines to Africa, help Africa enhance its capacity for localized vaccine production, and

E

Japanese drugmaker Shionogi's president

Isao Teshirogi (C), president of Japanese pharmaceutical firm Shionogi & Co., attends a press conference in Tokyo on March 4, 2022, over the company's COVID-19 vaccine under development.

E

Japanese drugmaker Shionogi's president

Isao Teshirogi, president of Japanese pharmaceutical firm Shionogi & Co., attends a press conference in Tokyo on March 4, 2022, over the company's COVID-19 vaccine under development.

E

Tunisia eases COVID-19 restrictions amid improved epidemiological situation

STORY: Tunisia eases COVID-19 restrictions amid improved epidemiological situation DATELINE: Feb. 27, 2022 LENGTH: 00:01:41 LOCATION: Tunis CATEGORY: SOCIETY/HEALTH SHOTLIST: 1. various of passengers walking out of Tunis Carthage International Airport 2. various of people having diner in restaurants STORYLINE: The Tunisian Ministry of Health on Friday announced measures that would ease the current COVID-19 restrictions in light of the improved situation in the country. "From March 1, the reception capacity in open spaces will increase to 100 percent. As for closed spaces, this capacity will be 75 percent, with the obligation to present the COVID-19 vaccine passport," said a ministry statement. The ministry added that from April 1, the reception capacity in closed spaces will also be tolerated at 100 percent, with the presence of a vaccine passport. "These decisions could be further rectified depending on the development of the pandemic situation in the country," it noted. For travelers from abroad, all

E

KM Biologics begins development of vaccine for novel coronavirus

KM Biologics (Kita Ward, Kumamoto City) has started to develop a vaccine for a new coronavirus infection. At a press conference held on April 25, President Nagasato said, "Our strength lies in the fact that we have skilled technicians and facilities from our days at the Research Institute for Chemotherapy and Serotherapy (KAKETSUKEN). As a member of the Meiji Group, we will do our utmost to expand this business. The new drug will be developed jointly with the National Institute of Infectious Diseases, the Institute of Medical Science of the University of Tokyo, and the National Institute of Biomedical Innovation, Health and Nutrition. The company will consider using its Kikuchi Research Center in Kikuchi City, Kumamoto Prefecture, and its Koshi Plant in Koshi City, Kumamoto Prefecture, which are capable of producing vaccines for 57 million new influenza cases. (Photo taken on May 25, 2020, location unknown, credit: Nikkan Kogyo Shimbun / Kyodo News Images)

E

China Biopharmaceutical,

Chinese biometrics are seen in a cluster of buildings in the Central Business District (CBD) in Beijing, China, on December 26, 2020. Sinovac Biotech Co., LTD., a subsidiary of Sinovac Biotech Co., LTD., received us $515 million for the further development, capacity expansion and production of novel Coronavirus inactivated vaccine and other development and operation activities of Sinovac. The investor, China Biopharmaceutical, an innovation-driven pharmaceutical group, will take a stake of about 15 per cent in The company.

E

China Biopharmaceutical,

Chinese biometrics are seen in a cluster of buildings in the Central Business District (CBD) in Beijing, China, on December 26, 2020. Sinovac Biotech Co., LTD., a subsidiary of Sinovac Biotech Co., LTD., received us $515 million for the further development, capacity expansion and production of novel Coronavirus inactivated vaccine and other development and operation activities of Sinovac. The investor, China Biopharmaceutical, an innovation-driven pharmaceutical group, will take a stake of about 15 per cent in The company.

E

China Biopharmaceutical,

Chinese biometrics are seen in a cluster of buildings in the Central Business District (CBD) in Beijing, China, on December 26, 2020. Sinovac Biotech Co., LTD., a subsidiary of Sinovac Biotech Co., LTD., received us $515 million for the further development, capacity expansion and production of novel Coronavirus inactivated vaccine and other development and operation activities of Sinovac. The investor, China Biopharmaceutical, an innovation-driven pharmaceutical group, will take a stake of about 15 per cent in The company.

E

China Biopharmaceutical,

Chinese biometrics are seen in a cluster of buildings in the Central Business District (CBD) in Beijing, China, on December 26, 2020. Sinovac Biotech Co., LTD., a subsidiary of Sinovac Biotech Co., LTD., received us $515 million for the further development, capacity expansion and production of novel Coronavirus inactivated vaccine and other development and operation activities of Sinovac. The investor, China Biopharmaceutical, an innovation-driven pharmaceutical group, will take a stake of about 15 per cent in The company.

E

China Biopharmaceutical,

Chinese biometrics are seen in a cluster of buildings in the Central Business District (CBD) in Beijing, China, on December 26, 2020. Sinovac Biotech Co., LTD., a subsidiary of Sinovac Biotech Co., LTD., received us $515 million for the further development, capacity expansion and production of novel Coronavirus inactivated vaccine and other development and operation activities of Sinovac. The investor, China Biopharmaceutical, an innovation-driven pharmaceutical group, will take a stake of about 15 per cent in The company.

E

China Biopharmaceutical,

Chinese biometrics are seen in a cluster of buildings in the Central Business District (CBD) in Beijing, China, on December 26, 2020. Sinovac Biotech Co., LTD., a subsidiary of Sinovac Biotech Co., LTD., received us $515 million for the further development, capacity expansion and production of novel Coronavirus inactivated vaccine and other development and operation activities of Sinovac. The investor, China Biopharmaceutical, an innovation-driven pharmaceutical group, will take a stake of about 15 per cent in The company.

E

China Biopharmaceutical,

Chinese biometrics are seen in a cluster of buildings in the Central Business District (CBD) in Beijing, China, on December 26, 2020. Sinovac Biotech Co., LTD., a subsidiary of Sinovac Biotech Co., LTD., received us $515 million for the further development, capacity expansion and production of novel Coronavirus inactivated vaccine and other development and operation activities of Sinovac. The investor, China Biopharmaceutical, an innovation-driven pharmaceutical group, will take a stake of about 15 per cent in The company.

E

China Biopharmaceutical,

Chinese biometrics are seen in a cluster of buildings in the Central Business District (CBD) in Beijing, China, on December 26, 2020. Sinovac Biotech Co., LTD., a subsidiary of Sinovac Biotech Co., LTD., received us $515 million for the further development, capacity expansion and production of novel Coronavirus inactivated vaccine and other development and operation activities of Sinovac. The investor, China Biopharmaceutical, an innovation-driven pharmaceutical group, will take a stake of about 15 per cent in The company.

E

China Biopharmaceutical,

Chinese biometrics are seen in a cluster of buildings in the Central Business District (CBD) in Beijing, China, on December 26, 2020. Sinovac Biotech Co., LTD., a subsidiary of Sinovac Biotech Co., LTD., received us $515 million for the further development, capacity expansion and production of novel Coronavirus inactivated vaccine and other development and operation activities of Sinovac. The investor, China Biopharmaceutical, an innovation-driven pharmaceutical group, will take a stake of about 15 per cent in The company.

E

China Biopharmaceutical,

Chinese biometrics are seen in a cluster of buildings in the Central Business District (CBD) in Beijing, China, on December 26, 2020. Sinovac Biotech Co., LTD., a subsidiary of Sinovac Biotech Co., LTD., received us $515 million for the further development, capacity expansion and production of novel Coronavirus inactivated vaccine and other development and operation activities of Sinovac. The investor, China Biopharmaceutical, an innovation-driven pharmaceutical group, will take a stake of about 15 per cent in The company.

E

China Biopharmaceutical,

Chinese biometrics are seen in a cluster of buildings in the Central Business District (CBD) in Beijing, China, on December 26, 2020. Sinovac Biotech Co., LTD., a subsidiary of Sinovac Biotech Co., LTD., received us $515 million for the further development, capacity expansion and production of novel Coronavirus inactivated vaccine and other development and operation activities of Sinovac. The investor, China Biopharmaceutical, an innovation-driven pharmaceutical group, will take a stake of about 15 per cent in The company.

E

China Biopharmaceutical,

Chinese biometrics are seen in a cluster of buildings in the Central Business District (CBD) in Beijing, China, on December 26, 2020. Sinovac Biotech Co., LTD., a subsidiary of Sinovac Biotech Co., LTD., received us $515 million for the further development, capacity expansion and production of novel Coronavirus inactivated vaccine and other development and operation activities of Sinovac. The investor, China Biopharmaceutical, an innovation-driven pharmaceutical group, will take a stake of about 15 per cent in The company.

E

China Biopharmaceutical,

Chinese biometrics are seen in a cluster of buildings in the Central Business District (CBD) in Beijing, China, on December 26, 2020. Sinovac Biotech Co., LTD., a subsidiary of Sinovac Biotech Co., LTD., received us $515 million for the further development, capacity expansion and production of novel Coronavirus inactivated vaccine and other development and operation activities of Sinovac. The investor, China Biopharmaceutical, an innovation-driven pharmaceutical group, will take a stake of about 15 per cent in The company.

E

China Biopharmaceutical,

Chinese biometrics are seen in a cluster of buildings in the Central Business District (CBD) in Beijing, China, on December 26, 2020. Sinovac Biotech Co., LTD., a subsidiary of Sinovac Biotech Co., LTD., received us $515 million for the further development, capacity expansion and production of novel Coronavirus inactivated vaccine and other development and operation activities of Sinovac. The investor, China Biopharmaceutical, an innovation-driven pharmaceutical group, will take a stake of about 15 per cent in The company.

E

China Biopharmaceutical,

Chinese biometrics are seen in a cluster of buildings in the Central Business District (CBD) in Beijing, China, on December 26, 2020. Sinovac Biotech Co., LTD., a subsidiary of Sinovac Biotech Co., LTD., received us $515 million for the further development, capacity expansion and production of novel Coronavirus inactivated vaccine and other development and operation activities of Sinovac. The investor, China Biopharmaceutical, an innovation-driven pharmaceutical group, will take a stake of about 15 per cent in The company.

E

China Biopharmaceutical,

Chinese biometrics are seen in a cluster of buildings in the Central Business District (CBD) in Beijing, China, on December 26, 2020. Sinovac Biotech Co., LTD., a subsidiary of Sinovac Biotech Co., LTD., received us $515 million for the further development, capacity expansion and production of novel Coronavirus inactivated vaccine and other development and operation activities of Sinovac. The investor, China Biopharmaceutical, an innovation-driven pharmaceutical group, will take a stake of about 15 per cent in The company.

E

China Biopharmaceutical,

Chinese biometrics are seen in a cluster of buildings in the Central Business District (CBD) in Beijing, China, on December 26, 2020. Sinovac Biotech Co., LTD., a subsidiary of Sinovac Biotech Co., LTD., received us $515 million for the further development, capacity expansion and production of novel Coronavirus inactivated vaccine and other development and operation activities of Sinovac. The investor, China Biopharmaceutical, an innovation-driven pharmaceutical group, will take a stake of about 15 per cent in The company.

E

China Biopharmaceutical,

Chinese biometrics are seen in a cluster of buildings in the Central Business District (CBD) in Beijing, China, on December 26, 2020. Sinovac Biotech Co., LTD., a subsidiary of Sinovac Biotech Co., LTD., received us $515 million for the further development, capacity expansion and production of novel Coronavirus inactivated vaccine and other development and operation activities of Sinovac. The investor, China Biopharmaceutical, an innovation-driven pharmaceutical group, will take a stake of about 15 per cent in The company.

E

Nikkei ends at over 29-year high

A roadside financial data screen in Tokyo on Nov. 11, 2020, shows the 225-issue Nikkei Stock Average ending at 25,349.60, its highest close in more than 29 years, on growing expectations for an early global economic recovery following progress in the development of a coronavirus vaccine.

E

Surge in Tokyo stocks

A roadside financial data screen in Tokyo shows the Nikkei Stock Average ending above the 23,000 line on Aug. 13, 2020, amid growing hopes for the development of a vaccine against the novel coronavirus.

E

Surge in Tokyo stocks

A roadside financial data screen in Tokyo shows the Nikkei Stock Average ending above the 23,000 line on Aug. 13, 2020, amid growing hopes for the development of a vaccine against the novel coronavirus.

E

WHO's Chan says Ebola vaccine trial results promising

World Health Organization Director General Margaret Chan speaks at a press conference in Geneva on July 31, 2015, about results from an interim analysis of the Guinea Phase III efficacy vaccine trial that showed VSV-EBOV is highly effective against Ebola. She said it is an extremely promising development. (Kyodo) ==Kyodo